Hyperbilirubinemia News and Research

RSS

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

New smartphone app helps identify severe jaundice in newborn babies

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study co-authored by researchers at UCL (University College London) and the University of Ghana.

3 Jun 2022

Researchers investigate gestational diabetes mellitus and its association with maternal and fetal outcomes

Researchers quantify the outcomes of pregnancies complicated by gestational diabetes.

30 May 2022

Preliminary results of AAV-mediated gene therapy for Crigler Najjar syndrome

Preliminary results from the European gene therapy trial for Crigler-Najjar syndrome, conducted by Genethon in collaboration with European network CureCN, were presented at the EASL (European Association for the Study of the Liver) annual International Liver Congress on June 26.

28 Jun 2021

Study analyzes link between maternal insecticide use during pregnancy and neonatal jaundice

The data of 61,751 pregnant women, out of approximately 100,000 collected by the Japan Environment and Children's Study analyzed the association between the maternal usage of insecticides and insect repellents during pregnancy and neonatal hyperbilirubinemia.

28 Aug 2020

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced preliminary results from its ongoing Phase I study of small activating RNA candidate MTL-CEBPA in advanced liver cancer.

4 Jun 2018

$FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL$

FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL

The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

17 Aug 2017

Stivarga receives expanded FDA approval for treatment of liver cancer

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.

28 Apr 2017

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.

26 Apr 2017

Study could provide novel therapeutic approach for preventing severe jaundice in newborn babies

For many newborn babies, an enzyme that breaks down the molecule bilirubin doesn't activate right away. The resulting bilirubin buildup can lead to jaundice, a typically harmless condition that causes a baby's skin to temporarily appear yellow.

6 Feb 2017

New method could help detect unconjugated bilirubin in newborn infants

A research group led by Project Professor Morioka Ichiro and Assistant Professor Iwatani Sota in collaboration with Doctor Miyawaki Atsushi have clinically proven that a fluorescent protein sourced from Japanese eel muscles can be used to accurately detect unconjugated bilirubin in newborns.

5 Jul 2016

Studies explore possible link between pediatric cancer and light therapy for newborn jaundice

Two new studies raise enough questions about a possible link between childhood cancer and light therapy for newborn jaundice that clinicians should exercise caution in prescribing the treatment for infants whose jaundice is likely to resolve on its own, a pediatric oncologist from Dana-Farber/Boston Children's Cancer and Blood Disorders Center argues in an editorial published today by the journal Pediatrics.

23 May 2016

Researchers suggest potential method of screening for jaundice in preterm infants

A research group led by Kobe University Graduate School of Medicine Project Professor MORIOKA Ichirou and Professor IIJIMA Kazumoto (Department of Pediatrics) has suggested a potential method of screening for jaundice (hyperbilirubinemia), a cause of cerebral palsy and loss of hearing in preterm infants with kyperbilirubinemia, using painless dermal monitoring.

29 Sep 2015

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.

19 Dec 2014

New study details weight loss patterns of breastfed newborns

Using weights obtained from over 100,000 Northern California babies, a new study is the first to detail the weight loss patterns of exclusively breastfed newborns. The results show that some breastfed babies lose weight faster and for a longer period than was previously recognized.

2 Dec 2014

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

25 Mar 2014

Neonatal jaundice linked to pediatric asthma risk

Researchers have found that neonatal hyperbilirubinemia is associated with an increased risk for childhood asthma.

7 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

4 May 2013